Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMBO-UC: Ustekinumab vs Infliximab vs Combination in Moderate-to-Severe Ulcerative Colitis
2023-506452-25-00Phase 2Authorised
- Sponsor
- Medical University of Lodz
- Start
- Mar 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial in autoimmune colitis comparing Infliximab monotherapy, Ustekinumab monotherapy and Infliximab + ustekinumab combination (3 arms). Primary endpoint: Clinical and endoscopic remission after induction. Planned start Mar 2025; status: authorised.
02
Drugs
ustekinumabinfliximab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2023-506452-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506452-25-00.